Relationship Between Preoperative Low-Density Lipoprotein Cholesterol and Periprocedural Myocardial Injury in Patients Following Elective Percutaneous Coronary Intervention in Southern China

Zhixiong Zhong*  
Jing Liu*  
Qifeng Zhang  
Wei Zhong  
Bin Li  
Cunren Li  
Zhidong Liu  
Min Yang  
Pingsen Zhao

* Contributed equally to this work

Corresponding Author: Pingsen Zhao, e-mail: zhaopingsen01@163.com, zhaopingsen@hotmail.com

Source of support: This study was supported by the National Key Research and Development Program of China (Grant No. 2016YFD0050405 to Dr. Pingsen Zhao), the National Key Research and Development Program of China (Grant No. 2017YFD0050405 to Dr. Pingsen Zhao), the National Science Foundation of Guangdong Province, China (Grant No. 2014A030307042 to Dr. Pingsen Zhao), the Medical Scientific Research Foundation of Guangdong Province, China (Grant No. A2016306 to Dr. Pingsen Zhao), the National Science Foundation of Guangdong Province, China (Grant No. 2016A030307031 to Dr. Pingsen Zhao), the Key Scientific and Technological Project of Meizhou People’s Hospital (Huangtang Hospital), Guangdong Province, China (Grant No. MPH/KSTP-20170102 to Pingsen Zhao), and the Key Scientific and Technological Project of Meizhou People’s Hospital (Huangtang Hospital), Guangdong Province, China (Grant No. MPH/KSTP-20170101 to Zhixiong Zhong)

Background:
Periprocedural myocardial injury (PMI) is known to be a predictor of postprocedural cardiovascular morbidity and mortality following a percutaneous coronary intervention (PCI). However, the correlation between low-density lipoprotein cholesterol and periprocedural myocardial injury in patients following elective PCI in southern China remains unclear. Therefore, we aimed to investigate the association of preoperative low-density lipoprotein cholesterol (LDL-C) levels with PMI in patients following elective PCI.

Material/Methods:
This study included 1942 consecutive patients who received elective PCI. Cardiac troponin I (cTnI) was used to assess perioperative myocardial injury. The peak cTnI was measured within 24 h after PCI, and the correlation between the cTnI value and the preoperative LDL level was studied.

Results:
The data suggest that the PCI patients with preprocedural LDL-C <100 mg/dl were strongly and independently correlated with less risk of PMI. Univariate logistic regression indicated that patients with preprocedural LDL-C of 70–99 mg/dl were correlated with lower risk of postprocedural cTnI elevation above 3×ULN (odds ratio [OR]: 0.762; 95% CI: 0.603–0.965; P<0.024) up to 20×ULN (OR: 0.730; 95% CI: 0.576–0.924; P<0.000) compared to those with preprocedural LDL-C ≥100 mg/dl. Moreover, patients with preprocedural LDL-C of <70 mg/dl were more strongly correlated with lower risk of postprocedural cTnI elevation above 3×ULN (OR: 0.641; 95% CI: 0.436–0.936; P<0.021) up to 20×ULN (OR: 0.476; 95% CI: 0.316–0.717; P<0.000).

Conclusions:
Our study demonstrated that PCI patients with lower preprocedural LDL-C were correlated with a lower risk of PMI in southern China.

MeSH Keywords: Cholesterol, LDL • Percutaneous Coronary Intervention • Troponin I

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/907400
Background

In modern interventional therapy, percutaneous coronary intervention (PCI) is the main method of revascularization in patients with coronary heart disease. PCI can significantly improve the symptoms of myocardial ischemia and reduce the incidence of vascular events in patients with coronary heart disease [1]. The incidence of perioperative myocardial injury (PMI), also known as myocardial infarction, did not substantially decreased despite technological advances and effective medical treatment [2]. Many clinical studies have shown that PMI is a predictor of adverse clinical outcomes after PCI. According to the Global Working Group on Myocardial Infarction (ESC/ACC/AHA/EHS/WHO), one of the criteria for definition of myocardial infarction (MI) is serum biomarkers (specifically troponin) elevation. Cardiac troponins are sensitive and specific markers of myocardial necrosis [3,4]. Previous cardiovascular magnetic resonance imaging studies showed that elevation of TnI after PCI indicates new irreversible myocardial injury [5]. They were benefited from the sensitivity, specificity, and prognosis of acute coronary syndrome ACS compare with creatine kinase (CK) and creatine kinase-muscle-brain (CK-MB) [6–9]. Postoperative cTnI > 1x the upper limit of normal (ULN) was interpreted as perioperative myocardial injury. Postoperative cTnI >3×ULN was diagnosed as myocardial infarction after PCI in 2007, and postprocedural cTnI >5×ULN, which was defined as PCI-related myocardial infarction in 2012 [10, 11].

Dyslipidemia is an independent risk factor for coronary heart disease. Clinical trials have shown that elevated LDL is linearly associated with coronary heart disease (CHD) [12]. Cardiovascular events and mortality could be reduced by 20% to 50% by interventions to lower levels of LDL-C. Researchers have suggested that patients with low LDL-C have reduced risk of postoperative myocardial injury in eastern China [13]. Although the lipid metabolism in urban and rural areas of southern China was reported to be associated with the special food culture, as well as genetic variants such as thalassemia, which may contribute to cardiovascular diseases in this area, little is known about whether the PCI patients with lower levels of LDL-C also have lower risk of PMI in southern China [14,15]. In this study, we explored the connection between preprocedural LDL-C levels and PMI in patients following elective PCI in southern China.

Material and Methods

Patient population

Eligibility screening was performed in patients undergoing coronary artery interventional therapy (PCI) at Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University. CHD patients were eligible for inclusion if they exhibited: (1) stable angina, or unstable angina and received elective PCI surgery, and (2) there were no ST segment elevation or non-ST segment elevation acute myocardial infarctions in the 4 weeks before the intervention. The major exclusion criteria were: (1) the patient died after PCI or angiography failed, (2) incomplete data on lipid files for patients, and (3) patients treated with atheroablative, distal protection devices, or aspiration thrombectomy.

From September 2014 to September 2016, a total of 1942 patients without acute myocardial infarction in the past 4 weeks who attempted to undergo elective PCI at Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, were eligible for this study. The present study was performed in accordance with the ethics standards laid down in the updated version of the 1964 Declaration of Helsinki and was approved by Human Ethics Committees of Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University, Guangdong province, China. All patients had signed informed consent.

Percutaneous coronary intervention

The indications for PCI were based on recommendations from the ACC/AHA, and all of patients were operated on by experienced interventional cardiologists. Patients were treated with aspirin (100–300 mg/day) and clopidogrel (300–600 mg) at least 2 h before PCI. All patients accepted a bolus of ungrad ed heparin 5000 U or 70 U/kg just before surgery, and a bolus of 2000–3000 U was added when the procedure lasted more than 1 h. The interventional cardiologist could decide on vascular access and PCI type based on the patient’s characteristics. The interventional cardiologist also could decide on total inflation times and inflation pressure of balloon, which is based on the technical properties of the balloon and the stent [16]. All patients continuously received aspirin and clopidogrel daily after PCI. Glycoprotein IIb/IIIa inhibitors were used at the surgeon’s discretion [12].

ECG monitoring

The 12-lead electrocardiogram was recorded before and after PCI in all patients, and in case of occurrence of symptoms that were considered as postoperative ischemic events. All patients underwent continuous electrocardiographic monitoring after PCI.

Biochemical measurements

Peripheral venous blood samples were collected before PCI for measuring lipid profiles. cTnI was detected before PCI and 24 h after PCI, as well as in the event of symptoms or signs that
suggested myocardial ischemia. The LDL-C level was tested by selective solubilization method (AU5400 analyzer, Beckman Coulter, CA). cTnI was determined using the PATHFAST cTnI-II (cardiac troponin I) Test (Mitsubishi Chemical, Tokyo, Japan). The ULN was interpreted as the 99th percentile of normal population with a total imprecision of <10%. The ULN of this test was 0.02 ng/mL. The peak value of cTnI was statistically analyzed within 24 h.

Statistics

The continuous variables and categorical variables are expressed as mean ± standard deviation, as percentage, or as frequencies with percentage, respectively. IBM SPSS Statistics 21.0 (IBM, Armonk, NY, USA) was used for all statistical analyses. Differences between groups based on LDL-C levels were analyzed using the $\chi^2$ test, Kruskal-Wallis test, or one-way ANOVA. The relationship of clinical parameters with postprocedural cTnI levels was tested by univariate linear regression analyses. The variables of P<0.05 in univariate linear regression were used as variables in a stepwise multivariate linear model. Successful normalization of cTnI after log-transformation was analysis using the Kolmogorov-Smirnov test. The correlation between LDL-C levels and the occurrence of postprocedural cTnI elevations above various multiples of ULN were determined by logistic regression. Based on the Guidelines for the Prevention and Treatment of Chinese Adult Dyslipidemia 2016, LDL-C was considered as the cut-off point (<70, 70–99, and ≥100 mg/dl). Additionally, variables were adjusted by the logistic model, and these variables were independently related to postprocedural cTnI levels. A probability value of P<0.05 was considered significant for this study.

Results

Clinical characteristics of the PCI patients

The study flow chart is shown in Figure 1. Between September 2014 and September 2016, 1942 patients were enrolled in the study. Table 1 demonstrates the baseline characteristics and lipids level of the PCI patients according to the cut-off point in LDL-C levels. Patients with lower levels of LDL-C tended to be male with a higher proportion of current drinking. Patients with higher LDL-C were less often male, had a history of prior myocardial infarction, and were smokers, and more often had hypercholesterolemia, higher levels of triglycerides, total cholesterol, NT-proBNP, and hemoglobin. However, no significant differences were observed in age, diabetes, hypertension, family history of CAD, preprocedural cTnI, and other medications among groups.

Procedural characteristics of the patients are presented in Table 2 according to the cut-off point in LDL-C levels. We found no significant differences in target vessel, target lesion site, number of vascular lesions, and target lesion type expect target vessels among groups with different LDL-C levels.

Correlation analysis of LDL-C levels with postprocedural cTnI elevation

Peak postprocedural cTnI >1×ULN, >3×ULN, >5×ULN, >10×ULN, and >15×ULN were detected in 1452 (74.8%), 1215 (62.6%), 1119(57.6%), 991 (51.0%), and 908 patients (46.8%), respectively. As shown in Table 3, simple linear regression analysis was performed to study the correlation between postprocedural cTnI (log-transformed) and other variables. The results demonstrated preoperative LDL-C levels were significantly associated with postprocedural cTnI elevation (r=0.077, P=0.001), and sex, age, prior CABG, current smoking, systolic blood pressure, diastolic blood pressure, NT-proBNP, and hemoglobin were positively related to postprocedural cTnI. Most importantly, stepwise multivariable analysis revealed that postprocedural cTnI was significantly correlated with sex, prior myocardial infarction, CABG, diabetes, current smoking, systolic blood pressure, diastolic blood pressure, HDL-C, LDL-C, triglyceride, NT-proBNP, preprocedural cTnI, distal, and number of branch target vessels. However, diabetes and triglyceride were inversely correlated with postprocedural cTnI levels.

Logistic regression analyses for LDL-C levels with postoperative cTnI elevation risk

As shown in Table 4, the association of the LDL-C subgroup with risk of postprocedural cTnI elevation were determined by logistic regression. Univariate logistic regression showed that patients with preprocedural LDL-C of 70–99 mg/dl were strongly correlated with lower risk of postprocedural cTnI elevation above 3×ULN up to >20×ULN compared to those with preprocedural LDL-C ≥100 mg/dl. Moreover, patients with preprocedural LDL-C of <70 mg/dl were more strongly associated with lower risk of postprocedural cTnI elevation above 3×ULN up to 20×ULN. In the adjusted logistic regression model, these associations were still present after adjusting for the all confounders according to the baseline of LDL-C levels (Table 4).
Discussions

To the best of our knowledge, this is the first study reporting the relationship of preprocedural LDL-C levels with PMI in patients undergoing PCI in southern China. The patients were carefully enrolled and sample size was robust in our study. The main finding of this study was that preprocedural LDL-C was correlated with postprocedural cTnI. Patients who had <70 mg/dl or 70–99 mg/dl were strongly and independently associated with less risk of PMI. Therefore, the present study provides important information for lipid-lowering therapy in PCI patients. High LDL-C level is not only a major cause of CAD, but also is related to the development of mature coronary plaques [17]. There are many traditional risk factors for cardiovascular disease, such as smoking, diabetes, obesity, hypertension, and

| Table 1. Baseline clinical characteristics. |
|------------------------------------------|
| Variable                        | LDL-C at baseline |
|                               | <70 mg/dl (n=151) | 70–99 mg/dl (n=489) | ≥100 mg/dl (n=1302) | P value |
| Age, y                         | 65.38±9.98        | 65.50±10.47        | 63.26±10.85        | <0.001 |
| Male, n (%)                   | 122 (80.8%)       | 385 (78.7%)        | 972 (74.7%)        | 0.075  |
| Prior MI, n (%)               | 19 (12.6%)        | 38 (7.8%)          | 42 (3.2%)          | 0.000  |
| Prior CABG, n (%)             | 23 (15.2%)        | 53 (10.8%)         | 109 (8.4%)         | 0.013  |
| Diastolic blood pressure, mmHg| 88 (58.3%)        | 267 (54.6%)        | 712 (54.7%)        | 0.692  |
| Current smoking, n (%)        | 61 (40.4%)        | 189 (38.7%)        | 490 (37.6%)        | 0.771  |
| Drinking, n (%)               | 15 (9.9%)         | 25 (5.1%)          | 53 (4.1%)          | 0.006  |
| HbA1C, %                      | 44.58±21.26       | 44.42±13.85        | 45.63±16.11        | 0.001  |
| LDL-C, mg/dl                  | 58.67±9.42        | 86.68±8.26         | 137.64±29.96       | <0.001 |
| TC, mg/dl                     | 122.38±144.15     | 395.02±524.51      | 130.42±431.50      | <0.001 |
| Triglyceride, mg/dl           | 136.73±29.47      | 162.17±145.62      | 181.88±125.02      | <0.001 |
| NT-proBNP, fmol/mL            | 4481.95±4407.46   | 2093.51±3787.81    | 1881.10±856.29     | <0.001 |
| Hemoglobin, g/dL              | 124.41±24.07      | 132.86±44.24       | 136.72±17.83       | <0.001 |
| Preprocedural cTnI, ng/mL     | 4.47±9.20         | 4.92±9.51          | 5.05±9.99          | 0.254  |
| Postprocedural cTnI, ng/mL    | 2.17±7.13         | 3.33±11.49         | 3.46±8.50          | 0.004  |
| Medications at study entry    |                     |                     |                     |        |
| Statins, n (%)                | 141 (93.4%)       | 470 (96.1%)        | 1254 (96.3%)       | 0.215  |
| Aspirin, n (%)                | 136 (90.1%)       | 436 (89.2%)        | 1168 (89.7%)       | 0.927  |
| Clopidogrel, n (%)            | 135 (89.4%)       | 438 (89.6%)        | 1139 (87.5%)       | 0.421  |
| β-Blockers, n (%)             | 126 (83.4%)       | 384 (78.5%)        | 1116 (85.7%)       | 0.001  |
| Calcium blockers, n (%)       | 17 (11.3%)        | 63 (12.9%)         | 189 (14.5%)        | 0.424  |
| ARBs, n (%)                   | 126 (83.4%)       | 398 (81.4%)        | 1076 (82.6%)       | 0.779  |
| PPI                            | 120 (79.5%)       | 344 (70.3%)        | 871 (66.9%)        | 0.005  |

ARBs – angiotensin receptor blockers; PPI – proton pump inhibitors; CABG – coronary artery bypass graft; cTnI – cardiac troponin I; LDL-C – low-density lipoprotein cholesterol; TC – total cholesterol; MI – myocardial infarction; NT-proBNP – N-terminal pro-brain natriuretic peptide; PCI – percutaneous coronary intervention. Values are expressed as mean ± standard deviation.
dyslipidemia. LDL-C is a well-established molecular risk factor. Li et al. found that the low preprocedural LDL-C levels were correlated with lower risk of PMI in PCI patients, and the risk of postprocedural cTnI elevation was increased by 12% to 20% due to increased 1-SD in LDL-C [13]. Similarly, Buturak et al. also observed a direct connection between preprocedural LDL-C levels and PMI in PCI patient with stable angina pectoris [18]. A cohort study that enrolled 302 consecutive patients reported that the ratios of LDL-C to high-density lipoprotein cholesterol (LDL-C/HDL-C) were significantly associated with PMI following elective PCI [19]. Furthermore, in recent years, experiments have shown that LDL-C levels <70 mg/dl were related to lower risk of cardiovascular events in secondary prevention populations. Thus, LDL-C plays an important role in secondary prevention and can reduce risk after PCI. According to the results of clinical studies, the hypothesis that “lower and better” in LDL-C level of patients with cardiovascular disease has been generally considered as optimal treatment [20,21].

Numerous studies have shown that statins, by decreasing LDL-C, can significantly reduce the incidence of myocardial injury or infarction after PCI [22]. Previous studies showed that statins have anti-inflammatory effect and anti-thrombotic properties, and improve endothelial function beyond merely decreasing LDL-C levels [23]. The pleiotropic effects of statins are proved by clinical research in vitro and in vivo, and such effects were obviously beneficial in reducing myocardial injury during PCI. In addition, the effect of lowering LDL-C level on myocardial injury after PCI is mainly due to its effect on plaques.

LDL-C level plays an important role in plaque vulnerability, which is associated with a high risk of periprocedural myocardial injury in patients undergoing elective stent implantation [17]. Clinical evidence showed that elevated LDL-C level is correlated with plaque characteristics and vulnerability, which were examined by intravascular ultrasound [24,25], optical coherence tomography [26], near-infrared spectroscopy [27], and dual-source computed tomography [28]. Vulnerable plaques have a large lipid core and a thin fibrous cap. Vulnerable plaques are prone to transfer, destruction, or exposure of thrombogenic material to the coronary flow, which may lead to thrombosis during and even following PCI. Therefore, intensive lipid-lowering therapy, especially LDL-C reduction, appears to slow plaque growth of minor lesions and reduce the occurrence of cardiovascular events in patients undergoing PCI [29,30].

Our research also revealed that there are some independent factors connected with postoperative myocardial injury, such as:

### Table 2. Procedural characteristics.

| Variable                        | LDL-C at baseline |
|---------------------------------|-------------------|
|                                 | <70 mg/dl (n=151) | 70–99 mg/dl (n=489) | ≥100 mg/dl (n=1302) | P value |
| **Target vessel**               |                   |                   |                   |         |
| LM                              | 19                | 67                | 972               | <0.001  |
| LAD                             | 141               | 467               | 42                | <0.001  |
| LCX                             | 114               | 378               | 109               | <0.001  |
| RCA                             | 119               | 407               | 325               | <0.001  |
| **Lesion location**             |                   |                   |                   |         |
| Proximal                        | 120               | 408               | 1092              | 0.499   |
| Middle                          | 135               | 412               | 1094              | 0.069   |
| Distal                          | 96                | 324               | 843               | 0.775   |
| Branch                          | 20                | 55                | 190               | 0.183   |
| Type B2/C                       | 93                | 320               | 863               | 0.511   |
| **Number of target vessel**     | 2.47±0.79         | 2.56±0.79         | 2.56±0.75         | 0.160   |
| **Number of stents implanted**  | 1.37±0.52         | 1.35±0.56         | 1.39±0.61         | 0.437   |
| **Total stent length, mm**      | 34.66±16.68       | 35.62±17.55       | 36.27±19.32       | 0.966   |
| **Bracket diameter**            | 3.13±0.403        | 3.13±0.44         | 3.12±0.45         | 0.759   |

LM – left main; LAD – left anterior descending; LCX – left circumflex; RCA – right coronary artery; Values are expressed as n (%), mean ± standard deviation or median with interquartile range.
| Variable                      | Simple regression | Multiple regression |
|-------------------------------|-------------------|---------------------|
|                               | Standard coefficient | P value | Standard coefficient | P value |
| Sex (Male, Female)            | 0.35              | 0.09               | 0.050               | 0.034   |
| Age, y                        | 0.25              | 0.219              | 0.25                | 0.192   |
| Prior MI, n (%)               | 0.23              | 0.267              | 0.051               | 0.03     |
| Prior CABG, n (%)             | 0.062             | 0.002              | 0.059               | 0.013    |
| Diabetes, n (%)               | -0.032            | 0.081              | -0.052              | 0.014    |
| Hypertension, n (%)           | 0.970             | 0.322              |                     |         |
| Hypercholesterolemia, n (%)   | 0.215             | 0.830              |                     |         |
| Current smoking, n (%)        | -0.087            | <0.001             | -0.096              | <0.001   |
| Drinking                      | 0.011             | 0.542              |                     |         |
| Systolic blood pressure mmHg | -0.144            | <0.001             | 0.096               | 0.001    |
| Diastolic blood pressure mmHg| -0.091            | <0.001             | 0.096               | <0.001   |
| HDL-C, mg/dl                 | 0.029             | 0.127              | 0.075               | 0.001    |
| LDL-C, mg/dl                 | 0.070             | <0.001             | 0.082               | <0.001   |
| TC, mg/dl                    | -0.015            | 0.390              |                     |         |
| Triglyceride, mg/dl          | -0.027            | 0.173              | -0.049              | 0.026    |
| NT-proBNP, mol/mL            | 0.073             | <0.001             | 0.089               | <0.001   |
| Platelets                    | 0.016             | 0.366              |                     |         |
| hemoglobin, mmol/L           | -0.038            | 0.044              |                     |         |
| Preprocedural cTnl, ng/mL     | 0.199             | <0.001             | 0.276               | <0.001   |
| Target vessel                |                   |                    |                     |         |
| LM                            | -0.021            | 0.248              |                     |         |
| LAD                           | 0.001             | 0.977              |                     |         |
| LCX                           | 0.260             | 0.363              |                     |         |
| RCA                           | -0.011            | 0.683              |                     |         |
| Lesion location               |                   |                    |                     |         |
| Proximal                      | 0.01              | 0.599              |                     |         |
| Middle                        | -0.007            | 0.714              |                     |         |
| Distal                        | -0.035            | 0.074              | 0.075               | 0.011    |
| Branch                        | 0.036             | 0.044              | 0.065               | 0.002    |
| Number of target vessels      | 0.054             | 0.144              | 0.087               | <0.001   |
| Number of type B2/C           | -0.028            | 0.206              |                     |         |
| Number of stents              | 0.004             | 0.839              |                     |         |
| Stent diameter                | -0.013            | 0.472              |                     |         |
| Total stent length            | -0.022            | 0.235              |                     |         |

CABG – coronary artery bypass graft; cTnl – cardiac troponin I; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol; TC – total cholesterol; MI – myocardial infarction; NT-proBNP – N-terminal pro-brain natriuretic peptide; SBP – systolic blood pressure; DBP – diastolic blood pressure; PCI – percutaneous coronary intervention. Values are expressed as mean ± standard deviation, median with interquartile range or n (%).
as sex, prior myocardial infarction, CABG, current smoking, systolic blood pressure, diastolic blood pressure, preprocedural cTnI, HDL-C, TC, triglyceride, NT-proBNP, and number of target vessels. Our findings may be important in developing instructions for health care and meditations for PMI patients with LDL-C undergoing PCI.

There are several limitations to this study. First, the presence of possible unmeasured variables might have confused the results, although we tried to adjust for known confounders. Secondly, the cTnI level was not tested continuously after PCI, but each patient received continuous electrocardiography. The cTnI level was additionally measured in the event of the occurrence of symptoms or signs suggestive of myocardial ischemia.

Table 4. Odds ratio (OR) for postprocedural cTnI elevation according to LDL-C levels.

| LDL-C (mg/dl) | No. of patients | Unadjusted model | Adjusted model |
|---------------|-----------------|-----------------|----------------|
| <70           | 152             | 0.802 (0.551–1.167) | 0.248 | 0.786 (0.520–1.189) | 0.255 |
| 70–99         | 489             | 0.863 (0.681–1.093) | 0.233 | 0.776 (0.598–1.006) | 0.055 |
| ≥100          | 1302            | Reference        | Reference |
| <70           | 152             | 0.651 (0.464–0.951) | 0.013 | 0.641 (0.436–0.936) | 0.021 |
| 70–99         | 489             | 0.812 (0.656–1.006) | 0.057 | 0.762 (0.603–0.965) | 0.024 |
| ≥100          | 1302            | Reference        | Reference |
| <70           | 152             | 0.744 (0.530–1.043) | 0.086 | 0.730 (0.502–1.063) | 0.012 |
| 70–99         | 489             | 0.795 (0.645–0.981) | 0.032 | 0.732 (0.581–0.923) | 0.008 |
| ≥100          | 1302            | Reference        | Reference |
| <70           | 152             | 0.652 (0.464–0.916) | 0.014 | 0.611 (0.416–0.896) | 0.012 |
| 70–99         | 489             | 0.747 (0.607–0.921) | 0.006 | 0.671 (0.531–0.84)  | 0.001 |
| ≥100          | 1302            | Reference        | Reference |
| <70           | 152             | 0.594 (0.419–0.843) | 0.003 | 0.577 (0.363–0.797) | 0.002 |
| 70–99         | 489             | 0.807 (0.655–0.995) | 0.045 | 0.733 (0.580–0.927) | 0.009 |
| ≥100          | 1302            | Reference        | Reference |
| <70           | 152             | 0.545 (0.372–0.770) | 0.001 | 0.476 (0.316–0.717) | 0.000 |
| 70–99         | 489             | 0.797 (0.645–0.984) | 0.035 | 0.730 (0.576–0.924) | 0.009 |
| ≥100          | 1302            | Reference        | Reference |
Conclusions

In summary, PCI patients with low preprocedural LDL-C are independently correlated with a lower risk of PMI. Patients with preprocedural LDL-C of <100 mg/dl had lower risk of periprocedural myocardial injury than those with preprocedural LDL-C of ≥100 mg/dl. Increased attention is needed to control LDL-C in southern China.

Acknowledgements

We would like to thank our colleagues in the Department of Neurology, Clinical Core Laboratory, and Center for Precision Medicine, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University for their helpful comments on the manuscript.

Conflicts of interest

None.

References:

1. Sanati H: Pre-procedural serum lipid profile and post-procedural myocardial injury. Res Cardiovasc Med, 2013; 2(4): 174–75
2. Zeng RX, Li JJ, Liao PD et al: Relationship of non-cardiac biomarkers with periprocedural myocardial injury in patients undergoing percutaneous coronary intervention. Int J Cardiol, 2016; 221: 76–33
3. Hamm CW, Goldmann BU, Heeschen C et al: Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med, 1997; 337(23): 1648–53
4. Feldman DN, Kim L, Rene AG et al: Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol, 2011; 77(7): 1020–30
5. Ari H, Emlek N, Ari S et al: The effect of high dose clostatol and rosuvastatin on periprocedural myocardial injury in patients with elective percutaneous coronary intervention. Acta Cardiol Sin, 2015; 31(4): 292–300
6. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol, 2000; 36(3): 959–69
7. Polanczyk CY, Lee TH, Cook Efet al: Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain. J Am Coll Cardiol, 1998; 32(1): 8–14
8. Zack: The prognostic value of serum troponin T in unstable angina. N Engl J Med, 1992; 327(3): 146–50
9. Galvani M, Ottani F, Ferrini D et al: Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation, 1997; 95(8): 2053–59
10. Aslanabadi N, Jafaripor I, Sadeghi S et al: Effect of vitamin D in the preoperative low-density lipoprotein cholesterol levels. Atherosclerosis, 2015; 242(2): 490–95
11. White, H.D., et al., Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction: Third universal definition of myocardial infarction. Circulation, 2012; 126(16): 2020–35
12. Zhang W, Ji F, Yu X, Wang X et al: Factors associated with uncontrolled LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention. Medicine, 2017; 96(1): e4569
13. Li XL, Li JJ, Guo YL et al: Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. J Clin Lipidol, 2014; 8(4): 423–32
14. Lao XQ, Zhang YH, Wong MC et al: The prevalence of metabolic syndrome and cardiovascular risk factors in adults in southern China. BMC Public Health, 2012; 12(1): 64
15. Pennell DJ, Udésion JE, Aral AE et al., American Heart Association Committee on Heart Failure and Transplantation of the Council on Cardiaciology and Council on Cardiovascular Radiology and Imaging: Cardiovascular function and treatment in β-thalassemia major. Circulation, 2013; 128(3): 281–308
16. Li Y, Guo YL, Zhu CG et al: Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dl. J Am Heart Assoc, 2013; 4(1): e001412
17. Kawakami R, Matsunomoto I, Shiomi M et al: Role of the low-density lipoprotein-cholesterol/high-density lipoprotein-cholesterol ratio in predicting serial changes in the lipid component of coronary plaque. Circ J, 2017; 81(10): 1439–46
18. Buturak A, Degirmencioglu A, Erkut M et al: Impact of increased admission lipid levels on periprocedural myocardial injury following an elective percutaneous coronary intervention. Coronary Artery Disease, 2015; 26(4): 333–40
19. Suzuki A, Ando H, Takashima H et al: Effects of polyunsaturated fatty acids on periprocedural myocardial infarction after elective percutaneous coronary intervention. Eurointervention, 2014; 10(7): 792–98
20. LaRosa JC, Grundy SM, Waters DD et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352(14): 1425–35
21. Ahn T, Suh SY, Lee K et al: Clinical outcomes according to the achievement of target low density lipoprotein-cholesterol in patients with acute myocardial infarction. Korean Circ J, 2017; 47(1): 31–55
22. Dai YP, Zhang HS, Zhang XG et al: Statin-zeatinum versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thorac Dis, 2017; 9(5): 1345–52
23. Kinoshita M1, Matsumura S, Sueyoshi M et al: Randomized trial of statin administration for myocardial injury: is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention? Circ J, 2007; 71(8): 1222–28
24. Nicholls SJ, Tuzcu EM, Sipahi I et al: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA, 2007; 297(5): 499–508
25. Nasu K, Terashima M, Habara M et al: Impact of cholesterol metabolism on coronary plaque vulnerability of target vessels: A combined analysis of virtual histology intravascular ultrasound and optical coherence tomography. JACC Cardiovasc Interv, 2013; 6(7): 746–55
26. Kатаoka Y, Hammadah M, Puri R et al: Plaque microstructures in patients with coronary artery disease who achieved very low-density lipoprotein cholesterol levels. Atherosclerosis, 2015; 242(2): 490–95
27. Goldstein JL, Maini B, Dixon SR et al: Detection of lipid-core plaques by intracoronary near-infrared spectroscopy identifies high risk of periprocedural myocardial infarction. Circ Cardiovasc Interv, 2011; 4(5): 429–37
28. Watabe H, Sato A, Akiyama D et al: Impact of coronary plaque composition on cardiac troponin elevation after percutaneous coronary intervention in stable angina pectoris: A computed tomography analysis. J Am Coll Cardiol, 2012; 59(21): 1881–88
29. Chhatravallina AK, Nicholls SJ, Nissen SE: The ASTEROID trial: Coronary plaque regression with high-dose statin therapy. Future Cardiol, 2006; 2(6): 651–54
30. Takayama T, Hiro T, Yamagishi M et al: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease. Circ J, 2009; 73(11): 2110–17